26.60
price up icon4.15%   1.06
after-market Handel nachbörslich: 26.60
loading

Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten

pulisher
Nov 21, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

Quest Partners LLC Purchases 32,884 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Nov 21, 2024
pulisher
Nov 21, 2024

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Nov 21, 2024
pulisher
Nov 20, 2024

Finansavisen - Finansavisen

Nov 20, 2024
pulisher
Nov 18, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Earns Overweight Rating from Analysts at Stephens - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Ideaya Biosciences Names Chief Commercial Officer - Contract Pharma

Nov 18, 2024
pulisher
Nov 18, 2024

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer – Company Announcement - Financial Times

Nov 18, 2024
pulisher
Nov 18, 2024

Stephens & Co. Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN

Nov 18, 2024
pulisher
Nov 16, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year LowTime to Sell? - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Ideaya Biosciences stock hits 52-week low at $27.51 - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

500: Something went wrong - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

Ideaya Biosciences stock hits 52-week low at $27.51 By Investing.com - Investing.com UK

Nov 15, 2024
pulisher
Nov 14, 2024

Janus Henderson Group PLC's Strategic Acquisition in IDEAYA Bios - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

IDEAYA Biosciences' SWOT analysis: biotech stock's potential in uveal melanoma treatment - Investing.com Australia

Nov 14, 2024
pulisher
Nov 13, 2024

(IDYA) Investment Analysis - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC's Strategic Acquisition of IDEAYA Biosciences Inc Shares - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise - 뉴스와이어

Nov 12, 2024
pulisher
Nov 12, 2024

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day - BioSpace

Nov 12, 2024
pulisher
Nov 12, 2024

IDEAYA Biosciences Announces Participation Jefferies London | Trending From Our Network - Chicago Star Media

Nov 12, 2024
pulisher
Nov 11, 2024

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - The Malaysian Reserve

Nov 11, 2024
pulisher
Nov 11, 2024

Ideaya nominates B7H3/PTK7 bispecific ADC as development candidate - BioWorld Online

Nov 11, 2024
pulisher
Nov 11, 2024

IDEAYA Announces Development Candidate Nomination of IDE034 | Trending From Our Network - Chicago Star Media

Nov 11, 2024
pulisher
Nov 09, 2024

Fiera Capital Corp Sells 45,590 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Research Analysts Set Expectations for IDYA FY2024 Earnings - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

90,000 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Purchased by General American Investors Co. Inc. - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

The 3.2% return this week takes IDEAYA Biosciences' (NASDAQ:IDYA) shareholders five-year gains to 258% - Simply Wall St

Nov 07, 2024
pulisher
Nov 07, 2024

Leerink Partnrs Issues Optimistic Estimate for IDYA Earnings - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

FY2024 EPS Forecast for IDEAYA Biosciences Raised by Analyst - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Leerink Partnrs Downgrades IDEAYA Biosciences (NASDAQ:IDYA) to Hold - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Trading Down 4.5%Here's Why - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to Market Perform at Leerink Partners - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023) - Yahoo Finance

Nov 05, 2024
pulisher
Nov 05, 2024

Wedbush Reiterates "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

IDEAYA Biosciences: Q3 2024 Financial and Clinical Progress - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire

Nov 04, 2024
pulisher
Nov 03, 2024

abrdn plc Buys Shares of 232,830 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

Ideaya Biosciences stock hits 52-week low at $28.04 By Investing.com - Investing.com South Africa

Nov 01, 2024
pulisher
Nov 01, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year LowHere's What Happened - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Ideaya Biosciences stock hits 52-week low at $28.04 - Investing.com

Nov 01, 2024
pulisher
Oct 30, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinic - GuruFocus.com

Oct 30, 2024
pulisher
Oct 29, 2024

Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

IDEAYA Biosciences' (IDYA) "Outperform" Rating Reaffirmed at Oppenheimer - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - The Malaysian Reserve

Oct 28, 2024
pulisher
Oct 28, 2024

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors – Company AnnouncementFT.com - Financial Times

Oct 28, 2024
pulisher
Oct 28, 2024

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase D - GuruFocus.com

Oct 28, 2024
pulisher
Oct 28, 2024

WRN inhibitor IDE-275 gains IND clearance for phase I study in MSI-high tumors - BioWorld Online

Oct 28, 2024
pulisher
Oct 28, 2024

IDEAYA Biosciences Reports Encouraging Clinical Data for IDE397 in MTAP-Deletion Urothelial Cancer and NSCLC - Defense World

Oct 28, 2024
pulisher
Oct 27, 2024

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $55.45 Average Price Target from Brokerages - MarketBeat

Oct 27, 2024
pulisher
Oct 25, 2024

IDYAIDEAYA Biosciences, Inc. Latest Stock News & Market Updates - StockTitan

Oct 25, 2024
pulisher
Oct 25, 2024

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 - Quantisnow

Oct 25, 2024
pulisher
Oct 24, 2024

Leerink Partnrs Has Pessimistic View of IDYA Q3 Earnings - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

UBS Group Initiates Coverage on IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat

Oct 24, 2024
pulisher
Oct 22, 2024

Where are the Opportunities in (IDYA) - Stock Traders Daily

Oct 22, 2024
pulisher
Oct 18, 2024

Analysts Offer Predictions for IDYA FY2024 Earnings - MarketBeat

Oct 18, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
Kapitalisierung:     |  Volumen (24h):